Testing Urine and Blood Cells to Study Urinary Tract Cancers
Studies cells from urine and blood to help predict outcomes in bladder cancer patients.
Plain-language title generated from the registry record
Registry title: Liquid Biospy for Urinary Cancers
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Urology DepartmentMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT06116396
- Record updated
- 7 November 2023
- Original description
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by CTCs.Read full original descriptionShow less
Use of Urinary Tumor Cells and Circulating Tumor Cells (CTCs) in the Prognosis and Therapy of Patients With Bladder (BCa) and Upper Urinary Tract (UTUC) Cancer"
The project aims to characterize the prognostic role of CTCs in Bladder cancer patients, with the specific aims to better stratify patients with non-muscle invasive bladder cancer at the first transurethral resection of tumor and to identify urothelial biomarker expressed by CTCs.
Inclusion: Diagnosis of urothelial neoplasia, naive for therapy.
Exclusion: Absence of previous neolpastic disease or genetic diseases.